<DOC>
	<DOCNO>NCT01568892</DOCNO>
	<brief_summary>Study ING116529 multicenter , randomize , study initial 7 day placebo- control , functional monotherapy phase quantify antiviral activity attributable dolutegravir ( DTG ) HIV-1 infected , ART-experienced adult experience virological failure Integrase inhibitor contain regimen ( current RAL ELV failure ) , evidence genotypic resistance RAL ELV study entry . Thirty subject randomize ( 1:1 ) receive either DTG 50mg BID ( Arm A ) Placebo ( Arm B ) current fail regimen 7 day ( RAL ELV discontinue prior dose DTG ) . At Day 8 , subject arm enter open label phase receive open label DTG 50mg BID optimize background regimen contain least one fully active drug .</brief_summary>
	<brief_title>Study Assessing Dolutegravir HIV-1 Infected Subjects With Virus Resistant Raltegravir and/or Elivitegravir</brief_title>
	<detailed_description>Study ING116529 multicenter , randomize , study initial 7 day placebo-controlled , functional monotherapy phase assess antiviral activity safety dolutegravir ( DTG , GSK1349572 ) contain regimen HIV-1 infect , ART-experienced adult virological failure integrase inhibitor ( INI ) contain regimen . Subjects must evidence genotypic resistance raltegravir [ RAL ] elvitegravir [ ELV ] Screening document current historical genotypic phenotypic resistance least two antiretroviral therapy drug class . The study design provide accurate measure intrinsic antiviral activity DTG 50mg twice daily versus placebo administer current fail regimen randomise double-blind phase Day 8 . This follow open label phase subject receive DTG 50mg twice daily optimize background regimen ( contain least one fully active drug ) subject longer derive clinical benefit DTG locally available . Thirty subject randomize ( 1:1 ) receive either DTG 50mg BID ( Arm A ) Placebo ( Arm B ) current fail regimen 7 day ( RAL ELV discontinue prior dose Day 1 ) . At Day 8 , subject arm enter open label phase receive open label DTG 50mg BID optimize background regimen contain least one fully active drug The primary analysis conduct last subject enrol complete randomised , double-blind phase Day 8 . Additional analysis may perform prior study closure ongoing subject transition locally available commercial DTG .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>Screening plasma HIV1 RNA ≥1000 copies/mL ARTexperienced , INIexperienced , DTG naïve Current virological failure raltegravir ( RAL ) elvitegravir ( ELV ) regimen The subject 's HIV1 show genotypic resistance RAL ELV Screening Subject stable ART least one month prior Screening Day 1 ( exception ETV , EFV NVP interrupt within 14 day Day 1 , see Exclusion Criterion ) Documented resistance least one drug two approve class ART integrase inhibitor Be able receive least one fully active drug part OBR Day 8 Women capable become pregnant must use appropriate contraception study ( define protocol ) Willing able understand provide sign dated write informed consent prior Screening . Women pregnant breast feed An active AIDSdefining condition Screening ( except cutaneous Kaposi 's sarcoma require systemic therapy CD4+ &lt; 200c/mm3 ) Moderate severe hepatic impairment define ChildPugh classification Anticipated need HCV therapy first 24 week study Recent history ( less equal 3 month ) upper low gastrointestinal bleed , exception anal rectal bleeding Allergy intolerance study drug component drug class Malignancy within past 6 month Treatment HIV1 therapeutic vaccine within 90 day Screening Treatment radiation therapy , cytotoxic chemotherapeutic agent immunomodulator within 28 day Screening Treatment agent , license ART , document vitro/vivo activity HIV1 within 28 day first dose investigational product ( exception entecavir require Hep B treatment ) Treatment etravirine , efavirenz , nevirapine within 14 day Day 1 ( etravirine may use coadministered lopinavir/ritonavir darunavir/ritonavir ) Treatment tipranivir/ritonavir , fosamprenavir , fosamprenavir/ritonavir within 28 day prior Screening Exposure experimental drug vaccine within either 28 day , 5 halflives test agent , twice duration biological effect test agent , ever long , prior first dose IP . Any acute verify Grade 4 laboratory abnormality ( exception Grade 4 lipid ) Screening ALT &gt; 5 time upper limit normal ( ULN ) Screening ALT ≥ 3X ULN bilirubin &gt; 1.5 X ULN ( 35 % direct bilirubin ) Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>ART-experienced</keyword>
	<keyword>GSK1349572</keyword>
	<keyword>Integrase inhibitor resistance</keyword>
	<keyword>Dolutegravir</keyword>
</DOC>